The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use
Patrick Amstutz discusses the properties of DARPins that make them ideal building blocks of multispecifics and use cases such as immuno oncology and radiotherapies.
Comments